Advanced Therapy Medicinal Products (ATMPs) are quite promising in this regard, which is why it’s attracting big numbers. The global ATMP market raised $19.9 billion in funding annually in 2020 alone, a 200% increase from 2019.
By the beginning of 2021, this investment will have supported more than 1,200 clinical trials of personalised cell and gene therapies across the globe, many of which will target the most serious forms of cancer, cardiovascular disease, and genetic disorders that, up until this point, could only be managed, not cured. The prognosis could soon be permanently altered thanks to ATMP innovators.
The majority of ATMP manufacturing processes are currently open and operator-driven. When using a patient's own cellular material as the therapeutic vehicle in autologous therapies, target patient populations can be as small as one.
That's a far cry from traditional biopharma facilities, which use automated, closed processes to consistently and dependably create large batches of the same drugs.
Flexibility is the key to finding a solution. As more ATMP products approach regulatory approval and commercial scale-out, manufacturers are turning to a new type of production facility, one that is flexible and future-ready and can quickly adapt as the market changes and new technologies are introduced.
Join us on 28th - 29th March, 2023 for the International Bioprocessing and Biologics Forum, in Berlin, Germany so you don't feel left out in the industry!
To register or learn more about the Forum please check here: https://bit.ly/3zxguXW
For more information and group participation, contact us: [email protected]
